Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
June 07 2016 - 7:30AM
Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a
leader in enabling precision medicine for oncology through
molecular markers and diagnostics, announced today that Panna
Sharma, President and CEO, will present a corporate overview at LD
Micro’s Sixth Invitational Conference on Wednesday, June 8, 2016 at
11:00 AM Pacific Time, at the Luxe Sunset Bel Air in Los Angeles,
CA.
The LD Micro Invitational is one of the most influential venues
in the micro-cap world with the upcoming conference taking place on
June 7th, 8th, and 9th, being expected to draw in over 200
companies and over 800 attendees. Throughout the conference, the
most unique publicly-traded companies in the micro-cap space will
be presenting to individual and institutional investors, analysts,
and members of the media.
If you are a private investor, institutional investor, or an
analyst interested in learning more about the conference, please
click here.
Investors and interested parties may listen to the live webcast
of Cancer Genetics’ presentation by
clicking http://wsw.com/webcast/ldmicro10/cgix.
About Cancer Genetics: Cancer Genetics, Inc. is
an emerging leader in DNA-based cancer diagnostics, servicing some
of the most prestigious medical institutions in the world. Our
tests target cancers that are difficult to diagnose and predict
treatment outcomes. These cancers include hematological, urogenital
and HPV-associated cancers. We also offer a comprehensive range of
non-proprietary oncology-focused tests and laboratory services that
provide critical genomic information to healthcare professionals,
as well as biopharma and biotech companies. Our state-of-the-art
reference labs are focused entirely on maintaining clinical
excellence and are both CLIA certified and CAP accredited and have
licensure from several states including New York State. We have
established strong research collaborations with major cancer
centers such as Memorial Sloan-Kettering, The Cleveland Clinic,
Mayo Clinic and the National Cancer Institute.
For more information, please visit or follow us:
Internet: www.cancergenetics.com Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward-Looking Statements: This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements pertaining to Cancer Genetics Inc.’s expectations
regarding the completion, timing, pricing and size of the offering
described in this press release constitute forward-looking
statements.
Any statements that are not historical fact (including, but not
limited to, statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates") should
also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development
and/or commercialization of potential products, risks of
cancellation of customer contracts or discontinuance of trials,
risks that anticipated benefits from acquisitions will not be
realized, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Cancer Genetics, Inc. Form 10-K for the year ended
December 31, 2015 and the Form 10-Q for the Quarter ended March 31,
2016 along with other filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. Cancer Genetics, Inc. disclaims any obligation to
update these forward-looking statements.
Contact:
Panna Sharma
CEO & President
Cancer Genetics, Inc.
201-528-9200
panna.sharma@cgix.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2023 to Aug 2024